Genetic predisposition to depression and inflammation impacts symptom burden and survival in patients with head and neck cancer: A longitudinal study

Henry, Mélissa; Harvey, Raphaële; Chen, Lawrence M.; Meaney, Michael J.; Nguyen, Thi Thu Thao; Kao, Han-Tin; Rosberger, Zeev; Frenkiel, Saul; Hier, Michael P.; Zeitouni, Anthony; Kost, Karen; Mlynarek, Alex; Richardson, Keith; Greenwood, Celia; Melnychuk, David; Gold, Phil; Chartier, Gabrielle; Black, Martin J.; Mascarella, Marco A.; MacDonald, Christina; Sadeghi, N.; Sultanem, Khalil; Shenouda, G.; Cury, Fabio; O’Donnell, Kieran J.

doi:10.1016/j.jad.2023.03.007

Cited by 3 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, radiotherapy is reasonably well tolerated. Acute and delayed potential radiotherapy-related toxicities are those that occur within the first 6 months post-treatment and beyond ( 86 ). Skin reactions, from redness to ulceration, can be the first sign of acute toxicity ( 87 ).…”

Section: Radiotherapymentioning

confidence: 99%

Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review)

Iancu,

Fulga,

Vesa

et al. 2024

Mol Clin Oncol

View full text Add to dashboard Cite

According to current predictions, one-fifth of all Americans will develop skin cancer during their lifetime. Cutaneous squamous cell carcinoma (cSCC) most commonly occurs in the head and neck region, which is the area of the body with the highest level of sun exposure. High-risk head and neck cSCC (HNcSCC) is a broad category with numerous high-risk factors that are associated with unfavorable results. In cSCC staging systems, clinical and tumor traits that are likely to result in poor outcomes are identified. Metastasis occurs in ~2.5% of patients with cSCC, most often in the local lymph nodes, and there is some indication that lymph node metastasis has a distinct pattern based on the tumor site. Current findings on tumor molecular targets have suggested the use of systemic treatments, particularly immunotherapy (such as cemiplimab, pembrolizumab and nivolumab), over radiotherapy or chemotherapy for this type of metastasis. However, when used simultaneously with immunotherapy, radiotherapy may be beneficial in the treatment of metastatic HNcSCC by improving the efficacy of immunotherapy. The present review aims to assess the existing literature on metastatic HNcSCC pathways and treatment options, in order to define current and future directions. Notably, there is an urgent need to identify patients who may benefit from local or systemic cancer treatments. The treatment of lymph node metastasis presents a therapeutic challenge and requires comprehensive management.

show abstract

Section: Radiotherapymentioning

confidence: 99%

Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review)

Iancu,

Fulga,

Vesa

et al. 2024

Mol Clin Oncol

View full text Add to dashboard Cite

show abstract

“…22 We computed a polygenic risk score for depression (PRS-D) based on a genome-wide association study of depression, 23 using the PRSoS software. 24 The same P value thresholding approach for calculating PRS-D, as described in Henry et al, 25 was used in this study. Specifically, we used the PRS-D at a P value threshold of P = .01, which demonstrated the greatest model fit for the association with symptom burden in this cohort (see Henry et al 25 ).…”

Section: Genotyping and Polygenic Risk Score Computation For Depressionmentioning

confidence: 99%

“…24 The same P value thresholding approach for calculating PRS-D, as described in Henry et al, 25 was used in this study. Specifically, we used the PRS-D at a P value threshold of P = .01, which demonstrated the greatest model fit for the association with symptom burden in this cohort (see Henry et al 25 ). A low PRS-D suggests that the individual has a low polygenic risk for depression relative to the sample population, and vice versa for a high PRS-D.…”

Section: Genotyping and Polygenic Risk Score Computation For Depressionmentioning

confidence: 99%

Genetic Risk For Depression and Quality of Life in Patients With Head and Neck Cancer

Henry,

Chen,

Ducharme

et al. 2024

JAMA Otolaryngol Head Neck Surg

Self Cite

View full text Add to dashboard Cite

ImportanceAlthough patients with head and neck cancer (HNC) have been shown to experience high distress, few longitudinal studies include a comprehensive evaluation of biopsychosocial factors affecting quality of life (QoL), including genetic risk for depression.ObjectiveTo identify factors at the time of cancer diagnosis associated with QoL scores at 3 months after treatment in patients newly diagnosed with a first occurrence of HNC.Design, Setting, and ParticipantsThis prospective longitudinal study of 1464 participants with a 3-month follow-up, including structured clinical interviews and self-administered measures was carried out at the Department of Otolaryngology Head and Neck Surgery at 2 tertiary care McGill University Affiliated Hospitals, McGill University Health Centre, and Jewish General Hospital. Eligible patients were adults newly diagnosed within 2 weeks with a primary first occurrence of HNC, had a Karnofsky Performance Scale score higher than 60, and an expected survival of more than 6 months. Two hundred and twenty-three patients (72%) consented to participate and completed the baseline questionnaire, and 71% completed the 3-month follow-up measures.ExposuresAn a priori conceptual model including sociodemographics, medical variables, psychosocial risk factors, and a polygenic risk score for depression (PRS-D) was tested.Main outcomes and measuresThe Functional Assessment of Cancer Therapy–Head and Neck measured QoL at baseline and at 3 months.ResultsParticipants were mostly men (68.7%), with a mean (range) age of 62.9 (31-92) years, 36.6% having a university degree, 35.6% living alone, and 71.4% diagnosed with advanced HNC with mostly cancers being of the oropharynx (42.2%), oral cavity (17%), and larynx (16.3%). QoL at 3 months after HNC diagnosis was associated with higher PRS-D (B = −4.71; 95% CI, −9.18 to −0.23), and a diagnosis of major depressive disorder within 2 weeks of an HNC diagnosis (B = −32.24; 95% CI, −51.47 to 13.02), lifetime suicidal ideation (B = −22.39; 95% CI, −36.14 to −8.65), living with someone (B = 12.48; 95% CI, 3.43-21.52), having smoked cigarettes in the past 30 days pre-HNC diagnosis (B = −15.50; 95% CI, −26.07 to −4.93), chemotherapy type (B = −11.13; 95% CI, −21.23 to −1.02), and total radiotherapy dose (Gy) (B = −0.008; 95% CI, −0.01 to −0.002).Conclusions and relevanceThis study identified the predictive value of a genetic predisposition to depression on QoL and function immediately after oncologic treatments. These findings highlight the potential importance of genetic profiling pretreatment to identify those most susceptible to experience QoL and functional compromise. Depression is a clear area of public health concern and should be a central focus in the treatment of patients with HNC.

show abstract

Psychosocial Oncology: Optimizing Outcomes through Interdisciplinary Care in Head and Neck Oncology

Henry

2023

Current Oncology

View full text Add to dashboard Cite

show abstract

Genetic predisposition to depression and inflammation impacts symptom burden and survival in patients with head and neck cancer: A longitudinal study

Cited by 3 publications

References 37 publications

Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review)

Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review)

Genetic Risk For Depression and Quality of Life in Patients With Head and Neck Cancer

Psychosocial Oncology: Optimizing Outcomes through Interdisciplinary Care in Head and Neck Oncology

Contact Info

Product

Resources

About